In a filing, NewAmsterdam Pharma Company NV revealed its Director Topper James N acquired Company’s shares for reported $25521.0 on Mar 26 ’25. In the deal valued at $22.49 per share,1,135 shares were bought. As a result of this transaction, Topper James N now holds 3,013,569 shares worth roughly $61.69 million.
Then, Michael H. Davidson bought 12,258 shares, generating $286,960 in total proceeds.
Before that, Douglas F Kling bought 16,539 shares. NewAmsterdam Pharma Company NV shares valued at $387,178 were divested by the Affiliate at a price of $23.41 per share.
H.C. Wainwright initiated its NewAmsterdam Pharma Company NV [NAMS] rating to a Buy in a research note published on December 30, 2024; the price target was $48. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in mid May with a ‘”a Buy”‘ rating. Scotiabank began covering NAMS with “Sector outperform” recommendation on March 14, 2024. Guggenheim started covering the stock on January 18, 2024. It rated NAMS as “a Buy”.
Price Performance Review of NAMS
On Monday, NewAmsterdam Pharma Company NV [NASDAQ:NAMS] saw its stock fall -5.93% to $20.47. Over the last five days, the stock has lost -14.71%. NewAmsterdam Pharma Company NV shares have fallen nearly -20.35% since the year began. Nevertheless, the stocks have fallen -9.82% over the past one year. While a 52-week high of $27.29 was reached on 01/02/25, a 52-week low of $15.19 was recorded on 02/25/25. SMA at 50 days reached $21.67, while 200 days put it at $20.13.
Levels Of Support And Resistance For NAMS Stock
The 24-hour chart illustrates a support level at 19.32, which if violated will result in even more drops to 18.17. On the upside, there is a resistance level at 21.84. A further resistance level may holdings at 23.21. The Relative Strength Index (RSI) on the 14-day chart is 36.07, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.56, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 81.29%. Stochastics %K at 13.48% indicates the stock is a buying.
How much short interest is there in NewAmsterdam Pharma Company NV?
A steep rise in short interest was recorded in NewAmsterdam Pharma Company NV stocks on 2025-03-14, growing by 1.43 million shares to a total of 4.34 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 2.91 million shares. There was a rise of 32.95%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 16, 2024 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $37 price target.
